@FierceBiotech: Party time at Array as Novartis bows out of PhIII binimetinib cancer program. Report | Follow @FierceBiotech
@JohnCFierce: College students with big ideas can shoot for some seed money from Xfund. Harvard-based--$100M. More from the WSJ | Follow @JohnCFierce
@DamianFierce: Blincyto, which sounds like it's related to the cells of blintzes, is the name of Amgen's new cancer drug. More | Follow @DamianFierce
> Milpitas, CA-based Protagonist Therapeutics has closed on the second tranche of its $18 million B round. The biotech is using the money to advance toward the clinic with PTG-100, an alpha-4-beta-7 integrin specific antagonist peptide for inflammatory bowel disease. Release
> CTI BioPharma received a $15 million milestone payment from Teva ($TEVA) related to the achievement of sales milestones for Trisenox (arsenic trioxide). Release
Medical Device News
@FierceMedDev: ICYMI: Illumina and Sequenom lay ongoing prenatal diagnostic patent feud to rest. Article | Follow @FierceMedDev
@EmilyWFierce: Britain's BTG scoops up pulmonology outfit PneumRx for up to $475M. Story | Follow @EmilyWFierce
> Zimmer makes a divestiture proposal to appease EU regulators in Biomet acquisition. Item
> Hospital requires use of wireless, wearable sensors to prevent bedsores. News
> HeartFlow's noninvasive test for coronary artery disease cleared by FDA. More
Pharma News
@FiercePharma: Powdered measles vaccine, safe in PhI, could aid vaccination in developing world. FierceVaccines article | Follow @FiercePharma
@EricPFierce: Sanofi, Viehbacher accused of kickback scheme in whistleblower suit. News | Follow @EricPFierce
@CarlyHFierce: Universal flu vaccine developer BiondVax mulling IPO. Globes | Follow @CarlyHFierce
> Incyte's Jakafi gets a boost with FDA nod for bone marrow disease. More
> Ranbaxy now faces product bans in Europe. Story
> Bayer and J&J push back against consolidation of Xarelto suits. News
Vaccines News
> Powdered measles vaccine, safe in PhI, could aid vaccination in developing world. Article
> Universal flu vax developer BiondVax mulling IPO: Globes. Item
> GSK, NIH gear up for Ebola vaccine trial expansion after success in PhI. Report
> Merck, NewLink Ebola vaccine trial shows no serious side effects so far. Story
> Novartis' Fluad off the hook in Italy following 19 deaths. Article
Pharma Manufacturing News
> EMA clears Novartis Fluad in deaths in Italy. Item
> Johnson Matthey buys former Glaxo facility in Scotland. More
> Strides Arcolab begins construction of $60M Malaysia facility. Report
> Some Indian drugmakers routinely toss out bad test results: Bloomberg. Story
> Germany, EU, join U.S. in banning India-made Ranbaxy products. Article